Acumen’s sabirnetug failed primary and secondary endpoints in Phase 2 ALTITUDE-AD despite significant amyloid plaque reduction in early Alzheimer’s disease.
Written By: Charvi Kalal, PharmD
Reviewed By: Pharmacally Editorial Team
Acumen Pharmaceuticals a clinical-stage biopharmaceutical company based in Newton, Massachusetts, announced on October 30, 2026, that its Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) failed to meet its primary endpoint in participants with early Alzheimer’s disease (AD). The humanized monoclonal antibody, which selectively targets soluble amyloid beta oligomers (AβOs), did not demonstrate a statistically significant slowing of cognitive and functional decline compared with placebo at either the 35 mg/kg or 50 mg/kg dose over 18 months.
Key secondary endpoints, including the Clinical Dementia Rating–Sum of Boxes (CDR-SB), also failed to achieve statistical significance. Despite significant amyloid plaque reduction at both doses, the clinical findings prompted Acumen to discontinue sabirnetug development and evaluate strategic options.
About Sabirnetug (ACU193)
Sabirnetug is a humanized monoclonal antibody developed to selectively target soluble AβOs, a pathogenic form of amyloid beta, rather than Aβ monomers or amyloid plaques. These soluble oligomers have been associated with neuronal binding, impaired synaptic function and neurodegeneration. The therapeutic approach was designed to investigate the hypothesis that soluble AβOs contribute to the early and persistent neurodegenerative processes in AD.
The U.S. Food and Drug Administration (FDA) granted sabirnetug Fast Track designation for early AD. Acumen was also investigating a subcutaneous formulation using Halozyme’s ENHANZE drug delivery technology and collaborating with JCR Pharmaceuticals on its Enhanced Brain Delivery (EBD) programme. Sabirnetug remains investigational and has not been approved for any indication.
ALTITUDE-AD Study Design
ALTITUDE-AD (NCT06335173) is a Phase 2, multicenter, randomized, double-blind, placebo-controlled trial initiated in 2024. The study enrolled 542 participants with early AD, including individuals with mild cognitive impairment or mild dementia due to AD, across the United States, Canada, the European Union and the United Kingdom.
Participants received intravenous sabirnetug at 35 mg/kg or 50 mg/kg, administered once every four weeks, or placebo. The primary endpoint was change from baseline in the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months. CDR-SB was among the key secondary efficacy endpoints.
Key Results
Primary and secondary endpoints: Sabirnetug failed to meet the primary iADRS endpoint at both doses. Key secondary efficacy endpoints, including CDR-SB, also did not achieve statistical significance, with no meaningful difference reported between either treatment arm and placebo.
Amyloid plaque reduction: Amyloid positron emission tomography (PET) standardized uptake value ratio (SUVr) analysis demonstrated statistically significant plaque reduction at both doses at weeks 36 and 76. However, this biological effect did not translate into a demonstrated clinical benefit on the reported cognitive and functional endpoints.
Safety: Acumen reported that sabirnetug was generally well tolerated, with amyloid-related imaging abnormalities with edema (ARIA-E) observed in approximately 10% of treated participants. The topline announcement did not provide a placebo comparison or detailed breakdown by dose and clinical characteristics.
Development Plans and Company Statement
Following the topline findings, Acumen plans to cease sabirnetug development, including the open-label extension portion of ALTITUDE-AD. The company will implement cash conservation measures and evaluate strategic options, including its EBD programme.
Daniel O’Connell, Chief Executive Officer of Acumen, expressed disappointment with the trial outcome while acknowledging the contributions of patients, caregivers, investigators, clinical trial sites and company employees involved in the programme.
Acumen expects additional fluid biomarker and imaging data from ALTITUDE-AD in the coming weeks, although it does not anticipate these analyses will change the efficacy conclusions. The company cautioned that further data or analyses could differ from, or change the interpretation of, the initial topline findings.
Clinical Interpretation
The ALTITUDE-AD results highlight an important distinction between biological activity and clinical efficacy in Alzheimer’s disease. Although sabirnetug significantly reduced amyloid plaque burden at both doses, it failed to demonstrate a corresponding improvement in cognitive and functional outcomes. The findings therefore do not support continued clinical development of sabirnetug in early AD based on the reported results.
However, the findings should not be interpreted as definitive evidence against the broader soluble AβO-targeting hypothesis. The announcement does not provide numerical treatment differences, confidence intervals, exact p-values or the magnitude of amyloid reduction. It also does not establish whether sabirnetug achieved adequate engagement of its intended soluble oligomer target in the brain at the tested doses.
The absence of detailed ARIA-E comparisons and other safety breakdowns also limits independent assessment of its safety profile. Full efficacy, biomarker, imaging and safety data will be important for understanding the reasons behind the clinical outcome. Until these data become available, the findings represent a setback for Acumen’s sabirnetug programme rather than a definitive conclusion about oligomer-targeting approaches in Alzheimer’s disease.
Reference
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint, Acumen Pharmaceuticals, 30 October 2026
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants with Early Alzheimer’s Disease (ALTITUDE-AD) (ALTITUDE-AD), ClinicalTrials.gov ID NCT06335173
About the Writer
Charvi Kalal (LinkedIn) is a Pharm.D intern and aspiring medical writer with hands-on experience in medical writing, clinical research, pharmacovigilance, and clinical pharmacy. She has experience in medical content writing through CliMed, along with exposure to ADR monitoring, prescription analysis, patient counselling, literature review, and research documentation. Her research focuses on ADR monitoring and reporting in breast cancer patients receiving targeted therapy. With certifications in GCP, biomedical research, scientific writing, and clinical research, she is passionate about transforming scientific evidence into accurate, engaging, and accessible healthcare content.